27 Dec 2023

HKSTP Applauds HighTide Therapeutics' IPO and First Clinical Trial Development in the City for the Innovative Treatment of Nonalcoholic Steatohepatitis (NASH) in Advancing Hong Kong’s Biotech Ecosystem

Hong Kong Science and Technology Parks Corporation (HKSTP) extends its warmest congratulations to partner company HighTide Therapeutics, Inc. (2511.HK) on the significant achievement of their initial public offering under Chapter 18A of the HKEX Main Board, and the development of the leading pipeline (HTD1801) in tackling metabolic and digestive diseases.